BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15233659)

  • 21. The efficacy of the third pump inhibitor--pantoprazole--in the short-term treatment of Chinese patients with duodenal ulcer.
    Chen TS; Chang FY; Ng WW; Lee FY; Hwang SJ; Lee SD
    Hepatogastroenterology; 1999; 46(28):2372-8. PubMed ID: 10522000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of proton pump inhibitors on the continuous real time (13)C-urea breath test.
    Shirin H; Frenkel D; Shevah O; Levine A; Bruck R; Moss SF; Niv Y; Avni Y
    Am J Gastroenterol; 2003 Jan; 98(1):46-50. PubMed ID: 12526935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
    Levine A; Shevah O; Shabat-Sehayek V; Aeed H; Boaz M; Moss SF; Niv Y; Avni Y; Shirin H
    Aliment Pharmacol Ther; 2004 Jul; 20(1):117-22. PubMed ID: 15225178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An audit of argon plasma coagulation, epinephrine injection, and proton-pump infusion therapy in the management of bleeding peptic ulcer disease.
    Yap LM; Hagan S; Craig A; Hebbard GG; Young GP; Bampton PA
    Endoscopy; 2004 Apr; 36(4):371-2; author reply 372-3. PubMed ID: 15057696
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group.
    Wurzer H; Schutze K; Bethke T; Fischer R; Luhmann R; Riesenhuber C
    Hepatogastroenterology; 1999; 46(27):1809-15. PubMed ID: 10430350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Are proton pump inhibitors safe?].
    Creutzfeldt W
    Internist (Berl); 1994 Dec; 35(12):1137-46. PubMed ID: 7883517
    [No Abstract]   [Full Text] [Related]  

  • 27. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
    Inadomi JM; McIntyre L; Bernard L; Fendrick AM
    Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosage of intravenous pantoprazole.
    Maltz C
    Am J Gastroenterol; 2003 Dec; 98(12):2803-5. PubMed ID: 14687838
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effective prescribing of proton pump inhibitors (PPI's) in the GMS Scheme.
    McGowan B; Bennett K; Tilson L; Barry M
    Ir Med J; 2005 Mar; 98(3):78-80. PubMed ID: 15869064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proton pump inhibitors and acute interstitial nephritis.
    Geevasinga N; Coleman PL; Webster AC; Roger SD
    Clin Gastroenterol Hepatol; 2006 May; 4(5):597-604. PubMed ID: 16630752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching between intravenous and oral pantoprazole.
    Pisegna JR
    J Clin Gastroenterol; 2001 Jan; 32(1):27-32. PubMed ID: 11154164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
    Uygun A; Kadayifçi A; Yeşilova Z; Savaş MC; Ateş Y; Karslioğlu Y; Ciğerim M; Bağci S; Dağalp K
    Turk J Gastroenterol; 2004 Dec; 15(4):219-24. PubMed ID: 16249974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial.
    Zargar SA; Javid G; Khan BA; Yattoo GN; Shah AH; Gulzar GM; Sodhi JS; Mujeeb SA; Khan MA; Shah NA; Shafi HM
    J Gastroenterol Hepatol; 2006 Apr; 21(4):716-21. PubMed ID: 16677158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The proton-pump inhibitors: similarities and differences.
    Horn J
    Clin Ther; 2000 Mar; 22(3):266-80; discussion 265. PubMed ID: 10963283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term prescribing of proton pump inhibitors in general practice.
    Hungin AP; Rubin GP; O'Flanagan H
    Br J Gen Pract; 1999 Jun; 49(443):451-3. PubMed ID: 10562744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous proton pump inhibition utilization and prescribing patterns escalation: a comparison between early and current trends in use.
    Law JK; Andrews CN; Enns R
    Gastrointest Endosc; 2009 Jan; 69(1):3-9. PubMed ID: 18718583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
    Ramdani A; Mignon M; Samoyeau R
    Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pantoprazole treatment does not invoke anti-inflammatory properties in vivo.
    Becker TL; Maróstica M; Ribeiro ML; de Mendonça S; Gambero A; Pedrazzoli J
    Int Immunopharmacol; 2004 Aug; 4(8):1051-7. PubMed ID: 15222979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
    Törüner M; Bektaş M; Cetinkaya H; Soykan I; Ozden A
    Turk J Gastroenterol; 2004 Dec; 15(4):225-8. PubMed ID: 16249975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.